Not bad at all
$Biotricity(BTCY.US$ • Biotricity's fiscal year 2024 revenue rose to $12.06 million, a 25% increase, with Q4 revenue up 15.9% to $3.2 million.
• Gross profit for the quarter was $2.3 million, a 48% year-over-year increase, with a gross margin of 71.5%.
• Operating expenses decreased by 17%, and the company is aiming for EBITDA neutrality and profitability soon.
• Strategic initiatives included the launch of Biocore Pro and HeartSecure, partnerships with industry leaders, and expansion in the U.S. and Canada.
• Biotricity plans to enter pulmonary and neurology fields through partnerships and is at an inflection point for scaling operations.
• Gross profit for the quarter was $2.3 million, a 48% year-over-year increase, with a gross margin of 71.5%.
• Operating expenses decreased by 17%, and the company is aiming for EBITDA neutrality and profitability soon.
• Strategic initiatives included the launch of Biocore Pro and HeartSecure, partnerships with industry leaders, and expansion in the U.S. and Canada.
• Biotricity plans to enter pulmonary and neurology fields through partnerships and is at an inflection point for scaling operations.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
